|
13th Annual Conference of the British HIV Association29 March–1 April 2007, Brighton, UK |
THE COMPLEX CHANGES IN TOLERABILITY AND ADHERENCE IN THOSE SWITCHING TO KALETRA TABLETS FROM KALETRA SOFT GEL CAPSULES
HIV Med 2007; 8(Suppl. 1):15 (abstract no. P20)
David Phillips2 and Mark Pakianathan1
1St George’s Hospital NHS Trust, London, UK, 2Mayday Healthcare NHS Trust, London, UK
AIMS AND OBJECTIVES: With the withdrawal of Kaletra (lopinavir/ritonavir, LPV/ r) as a soft gel capsule (SGC) and transition to tablets, data independent of pharma affiliation on the effects in HIV-positive patients has yet to be presented. We assessed the impact of this transition on tolerability and adherence in UK patients.
METHODS: Clinician administered questionnaire to patients on LPV/r SGC, pre- and 4 weeks post-switch to LPV/r tablets. The presence and severity score of nine named side effects (SEs) along with adherence was reported.
RESULTS: A total of 39 patients (13 female and 26 male) completed the two-part questionnaire (51% Black African and 38% White British). TOLERABILITY: Studying each SE in turn: 13–38% of patients improved by week 4, however between 5% and 26% of patients worsened. Looking at magnitude of improvement in SE score, only: ‘stool frequency’, ‘loose stool’ and ‘watery stool’ showed a significant reduction in SE score by week 4 (P<0.008, P<0.021 and P<0.028 respectively). When the scores for all nine SEs were added together, there was a mean reduction in ‘total’ SE score of 2.79 points [±2.77 (95% CI)]. ADHERENCE: 18 cases (46%) noted delayed dosing due to gastrointestinal (GI) SEs at week 0 and five cases (13%) at week 4 [72% reduction in delayed dosing]. Seven cases (18%) reported missing doses due to GI SEs at week 0 and three cases (8%) at week 4 [57% reduction in missed dosing].
CONCLUSIONS: Based on this UK group: despite an overall ‘population’ SE improvement after SCG to LPV/r tablet switch, individual responses vary widely. The large SE reduction in some masks worsening in a substantial number of others. Adherence did improve noticeably. We plan to extend this study to assess longer term responses.
2007-03-29
P20
Copyright © 2007 - British HIV Association (BHIVA) Reproduction of this abstract (other than one copy for personal reference) must be cleared through the BHIVA Organising Secretariat 1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD